Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $6.11, up 4.80% from its previous closing price of $5.83. In other words, the price has increased by $4.80 from its previous closing price. On the day, 1.43 million shares were traded. RLAY stock price reached its highest trading level at $6.15 during the session, while it also had its lowest trading level at $5.835.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.92 and its Current Ratio is at 20.92. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.
Jefferies Upgraded its Hold to Buy on September 10, 2024, whereas the target price for the stock was revised from $10.60 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 29 ’25 when Rahmer Peter sold 15,724 shares for $3.68 per share. The transaction valued at 57,864 led to the insider holds 377,998 shares of the business.
Rahmer Peter sold 1,359 shares of RLAY for $5,083 on Jul 28 ’25. The insider now owns 393,722 shares after completing the transaction at $3.74 per share. On Jul 29 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 18,380 shares for $3.68 each. As a result, the insider received 67,638 and left with 335,295 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1053433728 and an Enterprise Value of 430841728. For the stock, the TTM Price-to-Sale (P/S) ratio is 126.01 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 51.567 whereas that against EBITDA is -1.283.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.72, which has changed by -0.0714286 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $7.07, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 49.13%, while the 200-Day Moving Average is calculated to be 67.12%.
Shares Statistics:
It appears that RLAY traded 1.94M shares on average per day over the past three months and 1690780 shares per day over the past ten days. A total of 171.69M shares are outstanding, with a floating share count of 130.15M. Insiders hold about 24.51% of the company’s shares, while institutions hold 78.48% stake in the company. Shares short for RLAY as of 1757894400 were 22504700 with a Short Ratio of 11.61, compared to 1755216000 on 22740377. Therefore, it implies a Short% of Shares Outstanding of 22504700 and a Short% of Float of 15.83.
Earnings Estimates
. The current rating of Relay Therapeutics Inc (RLAY) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.05 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.23 and -$2.14 for the fiscal current year, implying an average EPS of -$1.7. EPS for the following year is -$1.75, with 7.0 analysts recommending between -$1.24 and -$2.67.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8.36M, resulting in an average revenue estimate of $12.97M. In the same quarter a year ago, actual revenue was $10.01M
